Cannabinoid CB1 receptors have been the focus of extensive studies since the first clinical results of rimonabant (SR141716) for the treatment of obesity and related metabolic disorders were reported in 2001. To further evaluate the properties of CB receptors, we have designed a new series of tetrazole-biarylpyrazoles. The various analogues were efficiently prepared and bio-assayed for binding to cannabinoid CB1 receptor. Six of the new compounds which displayed high in vitro CB1 binding affinities were assayed for binding to CB2 receptor. Noticeably, cyclopentyl-tetrazole (9a) demonstrated good binding affinity and selectivity for CB1 receptor (IC(50)=11.6nM and CB2/CB1=366).
Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists. Publishing Authors By Initials
Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists. Journal Published:
PUBLICATION TYPE: Research Support, Non-U.S. Gov
Journal: Bioorganic & medicinal chemistry letters
VOLUME: 18
Page Numbers: 2385-9
Journal Abbreviation:
ISSN: 1464-3405
DAY: 29
MONTH: 02
YEAR: 2008
Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists. Information
Number of References:
LANGUAGE: eng
NlmUniqueID: 9107377
Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists. Keywords Mesh Terms:
KEYWORDS:
MESH TERMS:
Chemical & Substance for Abstract: Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists. Information
Substance Name:
Registry Number:
Grant and Affiliation Information for Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists.
AFFILIATION: Small Molecule Group, Central Research Institute, Green Cross Corporation, 341 Bojeong-Dong, Giheung-Gu, Yongin, Gyunggi-Do 446-799, Republic of Korea.
Country: England
AGENCY:
GRANT:
ACRONYM:
MEDLINETA: Bioorg Med Chem Lett
REFSOURCE:
DATABASENAME:
ACCESSION NUMBER:
Number Hits: 0
Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists Related Publications